| Literature DB >> 36007072 |
K D W Hendriks1, J N Castela Forte1, W F Kok1, H E Mungroop2, H R Bouma3, T W L Scheeren2, M Mariani4, R H Henning1, A H Epema2.
Abstract
Data substantiating the optimal patient body temperature during cooling procedures in cardiac operations are currently unavailable. To explore the optimal temperature strategy, we examined the association between temperature management and survival among patients during cardiopulmonary bypass assisted coronary artery bypass grafting (CABG) procedures on 30-days and 5-year postoperative survival. Adult patients (n = 5,672, 23.6% female and mean (SD) age of 66 (10) years) operated between 1997 and 2015 were included, with continuous measured intraoperative nasopharyngeal temperatures. The association between mortality and patient characteristics, laboratory parameters, the lowest intraoperative plateau temperature and intraoperative cooling/rewarming rates were examined by multivariate Cox regression analysis. Machine learning-based cluster analysis was used to identify patient subgroups based on pre-cooling parameters and explore whether specific subgroups benefitted from a particular temperature management. Mild hypothermia (32-35°C) was independently associated with improved 30-days and 5-year survival compared to patients in other temperature categories regardless of operation year. 30 days and 5-year survival were 98% and 88% in the mild hypothermia group, whereas it amounted 93% and 80% in the severe hypothermia (<30°C). Normothermia (35-37°C) showed the lowest survival after 30 days and 5 years amounting 93% and 72%, respectively. Cluster analysis identified 8 distinct patient subgroups principally defined by gender, age, kidney function and weight. The full cohort and all patient subgroups displayed the highest survival at a temperature of 32°C. Given these associations, further prospective randomized controlled trials are needed to ascertain optimal patient temperatures during CPB.Entities:
Mesh:
Year: 2022 PMID: 36007072 PMCID: PMC9409584 DOI: 10.1371/journal.pone.0273370
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Patient characteristics, pre- and perioperative parameters.
| total | Normothermia | Mild | Moderate | Severe | p-value | |
|---|---|---|---|---|---|---|
| 35–37°C | 32–35°C | 30–32°C | <30°C | |||
|
| (n = 5672) | 261 (4.6%) | 1947 (34.3%) | 2899 (51.1%) | 566 (10.0%) | |
| Age (years) | 66 ± 9.7 | 65 ± 9.5 | 66 ± 9.7 | 66 ± 9.6 | 66 ± 9.9 | n.s |
| Female gender | 24% | 28% | 22% | 23% | 28% | 0.014 |
| BMI (kg∙m-2) | 27.3 ± 3.5 | 27.8 (25–30) | 27 (25–30) | 27 (25–29) | 27.1 (24–29) | <0.01 |
| Weight | 82.1 ± 13.1 | 83 ± 13.6 | 83 (74–92) | 81 (72–90) | 80 (72–89) | <0.01 |
| EuroSCORE | 0.002 | |||||
| Low (<2%) | 768 (24.4) | 41 (19.6) | 351 (25.7) | 339 (23.9) | 37 (23.7) | |
| Medium (2–5%) | 1044 (32.2) | 51 (24.4) | 453 (33.2) | 499 (35.1) | 41 (26.3) | |
| High (>5%) | 1337 (42.5) | 117 (56) | 560 (41.1) | 682 (41) | 78 (50.0) | |
|
| ||||||
| Haemoglobin (mmol/l) | 8.1 (7.5–9.1) | 8.2 (7.6–9.1) | 8.3 (7.7–9.1) | 8.1 (7.4–9.0) | 7.7 (6.6–8.9) | <0.01 |
| Platelet count (x10^9/l) | 237 (188–276) | 241 (190–275) | 242 (191–280) | 236 (188–275) | 223 (166–269) | <0.01 |
| Leukocyte count (x10^3/l) | 8.2 (6.4–9.2) | 8.7 (7.0–9.9) | 8.3 (6.5–9.5) | 8.0 (6.3–9.0) | 8.2 (6.5–9.5) | <0.01 |
| C-reactive protein (mg/l) | 24.7 (7–30) | 27.3 (25–30) | 22 (6–26) | 25 (6–33) | 32 (9–37) | 0.193 |
| Glucose (mmol/l) | 7.2 (5.3–8.6) | 6.8 (5.5–7.1) | 7.1 (5.3–8.2) | 7.1 (5.3–8.6) | 7.66 (5.3–9.3) | 0.050 |
| eGFR | 78 (60–93) | 93 (65–107) | 82 (62–99) | 75 (58–90) | 73 (56–87) | <0.01 |
|
| ||||||
| Duration of perfusion (min) | 102 (75–118) | 95 (69–116) | 95 (70–112) | 104 (79–120) | 116 (86–130) | <0.01 |
| Aortic cross clamp time (min) | 58 (43–73) | 35 (0–60) | 53 (38–66) | 62 (47–76) | 67 (49–80) | <0.01 |
|
| ||||||
| Haemoglobin (mmol/l) | 5.6 (5.2–6.1) | 5.8 (5.3–6.4) | 5.7 (5.2–6.2) | 5.6 (5.1–6.0) | 5.6 (5.1–6.1) | <0.01 |
Data presented as mean ± SD, number (proportion) or median (25th– 75th percentile). EuroSCORE gives the 30 days mortality risk. Significance tested by oneway ANOVA.
Fig 1Trend in nasopharyngeal temperatures during CPB assisted CABG over time.
Fig 25 year survival per categorized minimal nasopharyngeal temperature per time period, including (a) 1997–2002, (b) 2003–2009 and (c) 2010–2015.
Fig 3Survival per minimal nasopharyngeal temperature.
(a) 30-day survival, (b) 5-year survival corrected for 30-day survival (31 days– 5 year), (c) 5-year survival and (d) 5-year survival per degree.
Fig 4Survival relative to cooling and rewarming rate.
(a) Density plot of the cooling and rewarming rates. (b) Scatterplot cooling and rewarming rates with plateau temperature (c) Cooling rate– 5-year survival (d) Rewarming rate– 5-year survival.
Multivariate COX regression analysis.
| 30-days survival HR (95% CI) | p-value | 5-year survival HR (95% CI) | p-value | |
|---|---|---|---|---|
|
| ||||
| Age (years) | 1.02 (0.99–1.06) | 0.179 | 1.06 (1.04–1.07) | <0.001 |
| Female gender | 0.60 (0.31–1.16) | 0.130 | 0.60 (0.50–0.84) | 0.001 |
| BMI (kg∙m-2) | 0.98 (0.91–1.05) | 0.509 | 0.99 (0.97–1.03) | 0.808 |
|
| ||||
| Haemoglobin (mmol/l) | 0.91 (0.72–1.13) | 0.386 | 0.95 (0.87–1.05) | 0.304 |
| Platelet count (x10^9/l) | 1.00 (0.997–1.00) | 0.940 | 1.00 (1.00–1.00) | 0.002 |
|
| ||||
| Low risk (<2.5%) | Reference | Reference | ||
| Medium risk (2.5–5%) | 0.242 (0.06–0.99) | 0.048 | 0.96 (0.66–1.40) | 0.826 |
| High risk (>5%) | 2.11 (0.81–5.52) | 0.126 | 1.43 (0.98–2.08) | 0.061 |
|
| 6.28 (3.64–10.87) | <0.001 | 2.39 (1.88–3.04) | <0.001 |
|
| ||||
| Duration of perfusion | 1.10 (1.03–1.17) | 0.003 | 1.11 (1.07–1.14) | <0.001 |
|
| ||||
| Normothermia (35–37°C) | Reference | Reference | ||
| Mild hypothermia (32–35°C) | 0.15 (0.07–0.34) | <0.001 | 0.36 (0.25–0.52) | <0.001 |
| Moderate hypothermia (30–32°C) | 0.24 (0.12–0.50) | <0.001 | 0.39 (0.27–0.56) | <0.001 |
| Severe hypothermia (<30°C) | 0.61 (0.25–1.53) | 0.294 | 0.52 (0.31–0.87) | 0.01 |
Hazard ratio (HR) with 95% confidence interval (C.I.) on mortality in CABG surgery. EuroSCORE gives the 30 days mortality risk.
Patient characteristics and preoperative factors based on putative pre-cooling cluster membership for 4351 patients.
| Cluster 1 | Cluster 2 | Cluster 3 | Cluster 4 | Cluster 5 | Cluster 6 | Cluster 7 | Cluster 8 | |
|---|---|---|---|---|---|---|---|---|
|
| 54 | 1045 | 508 | 1323 | 358 | 16 | 639 | 402 |
| 80 | 100.0 | 99 | 99 |
| 94 |
| 99 | |
|
|
| 28.9 (3.7) |
| 26.3 (2.9) |
| 28.2 (3.5) | 24.9 (2.5) | 26.7 (3.0) |
|
|
|
|
| 71.4 (5.7) | 67.5 (8.9) | 62.2 (10.1) |
| 66.1 (8.9) |
|
| 250 (64) | 235 (50) | 337 (90) | 212 (43) | 254 (73) | 236 (64) | 260 (82) | 153 (48) |
|
|
|
| 75.4 (22.5) | 70.1 (17.5) | 75.9 (25.3) |
|
| 76.3 (22.3) |
|
| 9.2 (3.3) |
|
| 7.2 (1.7) | 8.6 (2.8) | 8.7 (1.8) |
| 8.5 (3.4) |
|
| 7.4 (1.3) |
| 8.2 (0.9) |
| 7.8 (1.1) | 6.9 (0.6) |
|
|
|
|
|
|
| 7.0 (2.0) | 6.9 (2.7) |
|
| 7.0 (2.4) |
| Creatinine (μmol/l) | 265 (141) |
| 102 (27) | 102 (22) | 91 (30) | 972 (241) |
|
|
|
| 12.9#$ | 0.8$ | 4.1# | 2.3 | 2.2 | 18.8#$ | 2.7 | 2.5 |
|
| 64.8#$ | 5.2$ | 20.9# | 16.2# | 10.6$ | 50.0#$ | 15.8# | 17.4# |
|
| Patients with moderate-to-severe decrease in kidney function | Overweight, younger male patients with good kidney function and low urea | Male patients with mild kidney function impairment, high inflammatory markers and urea | Older, male patients with moderate-normal lab values | Obese female patients with a mild kidney function impairment | Patients with kidney failure | Older female patients with a moderate decrease in kidney function | Male patients with marked anaemia |
Results are presented as mean(SD), results that are distinct for a particular cluster are bolded for emphasis. Comparisons are based on analysis of variance or chi-squared tests. Pairwise-comparison between clusters for mortality are calculated with the Tukey HSD test. Clusters marked with # differed significantly compared to cluster 2, and clusters marked with $ differed significantly compared to cluster 3, all with p <0.001.
Fig 55-year survival per pre-cooling cluster.
(a) 5-year survival is shown and differentiated for all 8 machine learning-based clusters. (b) survival for different nasopharyngeal temperature during CPB within each pre-cooling phenotype. Statistically tested using the long-rank test.